-
-
-
Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer
- 2023.11.1 ｜ 抄読会論文
- 抄読会要旨 今村光佑...
-
-
-
-
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study
- 2023.10.27 ｜ 抄読会論文
- 抄読会要旨 猪山慎治...
-
-
-
-
High yield of pleural cell-free DNA for diagnosis of oncogenic mutations in lung adenocarcinoma
- 2023.10.12 ｜ 抄読会論文
- 抄読会要旨 木村俊貴...
-
-
-
-
Efzofitimod for the Treatment of Pulmonary Sarcoidosis
- 2023.09.21 ｜ 抄読会論文
- 抄読会要旨 岡林比呂子...
-
-
-
-
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer N Engl J Med. 2023 Jun 3. doi: 10.1056/NEJMoa2302983. Online ahead of print.
- 2023.07.4 ｜ 抄読会論文
- 抄読会要旨 猿渡功一...
-
-
-
-
Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer
- 2023.05.8 ｜ 抄読会論文
- 抄読会要旨 御任玲美...
-
-
-
-
A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy
- 2023.05.8 ｜ 抄読会論文
- 抄読会要旨 猪山慎治...
-
-
-
-
Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation. J Allergy Clin Immunol. 2023 Feb 3:S0091-6749(23)00144-6.
- 2023.04.24 ｜ 抄読会論文
- 抄読会要旨 穴井盛靖...
-
-
-
-
Dupilumab increases aspirin tolerance in NSAID exacerbated respiratory disease (N-ERD) Schneider S, et.al: Eur Respir J. 2022;in press
- 2023.04.21 ｜ 抄読会論文
- 抄読会要旨 吉田知栄子...
-
-
-
-
2023年度実績
- 2023.04.14 ｜ 研究実績
- 2023年度業績 【英文論文】 Hamada S, Muramoto K, Aka...
-
